Human integrated tumor immunology discovery engine (Hi-TIDe)
Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne
Head of clinical Mass spectromotry unit
Center of experimental therapeutics
Phone +41 79 900 55 30
Our main goal is to identify clinically relevant cancer specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using mass-spectrometry (MS), currently the only methodology to unbiasedly identify HLA binding peptides that are presented in vivo to cytotoxic T cells.
Research group projects
MS-based immunopeptidomics with proteomics, genomics, and transcriptomics to identify tumor-associated antigens, neoantigens and post translationally modified peptides.
We developed a high-throughput and in depth MS-based immunopeptidomics pipeline that now enables robust and reproducible sample preparation and measurement of HLA class I and HLA class II peptides. We are currently applying this methodology to identify tumor-associated HLA ligands extracted from cell lines and tumor tissues.
- We have initiated fundamental discovery work to elucidate how tumor cells present antigens and what are the bases of tumor immunogenicity.
- We are investigating the differences between tumor types in terms of antigen presentation and how drugs modulate the immunopeptidome.
- In collaboration with the Vital-IT group (SIB), we have established a continuous bio-informatics pipline enabling direct identification of neoantigens by combining genomic information derived from exome-seq analysis with measured immunopeptidomics data.
- In collaboration with Prof. David Gfeller, we are improving the performance of HLA binding prediction tools by training them with our measured immunopeptidomics data.
- This platform will be used to identify personalized neo-antigens from patients samples collected by the CTE team. These tumor-specific antigens will be further developed into personalized cancer vaccines or to enrich tumor-reactive and antigen-specific T cells for adoptive T cell-based therapies.